Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

Malcolm A. Smith, Oliver A. Hampton, C. Patrick Reynolds, Min H. Kang, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, Jianrong Wu, Raushan T. Kurmasheva, David A. Wheeler, Peter J. Houghton

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Fingerprint Dive into the research topics of 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673'. Together they form a unique fingerprint.

Medicine & Life Sciences